DE60010089D1 - Beta-carbolin arzneistoffprodukte - Google Patents

Beta-carbolin arzneistoffprodukte

Info

Publication number
DE60010089D1
DE60010089D1 DE60010089T DE60010089T DE60010089D1 DE 60010089 D1 DE60010089 D1 DE 60010089D1 DE 60010089 T DE60010089 T DE 60010089T DE 60010089 T DE60010089 T DE 60010089T DE 60010089 D1 DE60010089 D1 DE 60010089D1
Authority
DE
Germany
Prior art keywords
carboline
beta
drug products
drug
products
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60010089T
Other languages
English (en)
Other versions
DE60010089T2 (de
Inventor
R Anderson
J Hartauer
A Kral
A Stephenson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lilly Icos LLC
Original Assignee
Lilly Icos LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22520112&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60010089(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Icos LLC filed Critical Lilly Icos LLC
Publication of DE60010089D1 publication Critical patent/DE60010089D1/de
Application granted granted Critical
Publication of DE60010089T2 publication Critical patent/DE60010089T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
DE60010089T 1999-08-03 2000-08-01 Beta-carbolin arzneistoffprodukte Expired - Lifetime DE60010089T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14704899P 1999-08-03 1999-08-03
US147048P 1999-08-03
PCT/US2000/020981 WO2001008688A2 (en) 1999-08-03 2000-08-01 Beta-carboline drug products

Publications (2)

Publication Number Publication Date
DE60010089D1 true DE60010089D1 (de) 2004-05-27
DE60010089T2 DE60010089T2 (de) 2004-10-14

Family

ID=22520112

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60010089T Expired - Lifetime DE60010089T2 (de) 1999-08-03 2000-08-01 Beta-carbolin arzneistoffprodukte

Country Status (33)

Country Link
EP (1) EP1200092B1 (de)
JP (1) JP4456788B2 (de)
KR (1) KR20020063842A (de)
CN (2) CN101134019A (de)
AR (1) AR033953A1 (de)
AT (1) ATE264680T1 (de)
AU (1) AU773666B2 (de)
BR (1) BR0012901A (de)
CA (1) CA2380087C (de)
CO (1) CO5200849A1 (de)
CZ (1) CZ300151B6 (de)
DE (1) DE60010089T2 (de)
DK (1) DK1200092T3 (de)
DZ (1) DZ3180A1 (de)
EA (1) EA004302B9 (de)
ES (1) ES2220506T3 (de)
HK (1) HK1044278B (de)
HR (1) HRP20020091B1 (de)
HU (1) HU229443B1 (de)
IL (1) IL147642A0 (de)
MX (1) MXPA02001197A (de)
MY (1) MY125428A (de)
NO (1) NO321602B1 (de)
NZ (1) NZ516613A (de)
PE (1) PE20010480A1 (de)
PL (1) PL199469B1 (de)
PT (1) PT1200092E (de)
SK (1) SK286365B6 (de)
SV (1) SV2002000137A (de)
TW (1) TWI235658B (de)
UA (1) UA71629C2 (de)
WO (1) WO2001008688A2 (de)
ZA (1) ZA200200825B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4491200A (en) * 1999-08-03 2001-02-19 Lilly Icos Llc Beta-carboline pharmaceutical compositions
US8063214B2 (en) * 2004-10-28 2011-11-22 Dr. Reddy's Laboratories Limited Polymorphic forms of tadalafil
PL1808164T3 (pl) * 2006-01-05 2009-06-30 Teva Pharma Sposób z granulacją na mokro do wytwarzania kompozycji farmaceutycznych aripiprazolu
DE102007028869A1 (de) 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
MD4009C2 (ro) * 2008-07-15 2010-08-31 Институт Химии Академии Наук Молдовы Utilizarea 1-metil-4-(N-metilaminobutil-4)-β-carbolinei în calitate de remediu antituberculos
DE102009033396A1 (de) 2009-07-16 2011-01-20 Ratiopharm Gmbh Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung
DE102009035211A1 (de) 2009-07-29 2011-02-17 Ratiopharm Gmbh Copräzipitate umfassend einen Phosphodiesterase-5-Inhibitor (PDE-5-Inhibitor) und einen pharmazeutisch verträglichen Trägerstoff, ihre Herstellung und Verwendung
WO2012085927A2 (en) * 2010-12-02 2012-06-28 Mylan Laboratories, Limited Tadalafil compositions
WO2012095151A1 (en) 2010-12-23 2012-07-19 Zaklady Farmaceutyczne Polpharma Sa Solid pharmaceutical dosage forms comprising tadalafil and methods of preparation thereof
WO2012107092A1 (en) 2011-02-10 2012-08-16 Synthon Bv Pharmaceutical composition comprising tadalafil and a cyclodextrin
RU2013141446A (ru) 2011-02-10 2015-03-20 Синтон Бв Фармацевтическая композиция, содержащая тадалафил и циклодекстрин
WO2012107090A1 (en) 2011-02-10 2012-08-16 Synthon Bv Granulated composition comprising tadalafil and a disintegrant
JP5930686B2 (ja) * 2011-12-07 2016-06-08 株式会社トクヤマ 溶解性および安定性の向上した難溶性医薬品原体及びその製造方法
KR102268696B1 (ko) 2012-03-15 2021-06-23 메르크 파텐트 게엠베하 전자 소자
WO2014003678A1 (en) * 2012-06-28 2014-01-03 Xspray Microparticles Ab Pharmaceutical compositions comprising ambrisentan and solid dispersion particles containing tadalafil
WO2014003677A1 (en) * 2012-06-28 2014-01-03 Xspray Microparticles Ab Pharmaceutical compositions comprising solid dispersion particles containing tadalafil
CN105310984A (zh) * 2014-06-10 2016-02-10 合肥贝霓医药科技有限公司 一种pde5抑制剂的超微粉体及其制备方法
EP3111929B1 (de) * 2014-06-24 2018-08-29 Wooshin Labottach Co., Ltd. Im mund zerfallende filmformulierung mit tadalafil und herstellungsverfahren dafür
SI3172207T1 (sl) 2014-07-23 2019-06-28 Krka D.D., Novo Mesto Proces za pripravo zaviralca CGMP-fosfodiesteraze in oralne farmacevtske formulacije, ki obsega koprecipitate tadalafila
JP2016106139A (ja) * 2016-03-07 2016-06-16 株式会社トクヤマ 溶解性および安定性の向上した難溶性医薬品原体及びその製造方法
CA3086881A1 (en) * 2017-12-26 2019-07-04 Ftf Pharma Private Limited Liquid oral formulations for pde v inhibitors
HUE052118T2 (hu) 2018-01-10 2021-04-28 Gap S A Tadalafil szuszpenziót tartalmazó lágy zselatinkapszulák
CN110638770B (zh) * 2019-10-25 2022-04-05 株洲千金药业股份有限公司 他达拉非片剂的制备方法及以该方法制得的片剂
WO2023227185A1 (en) * 2022-05-27 2023-11-30 Rontis Hellas S.A. Improved pharmaceutical composition containing tadalafil and nanomilling process for the preparation thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618845A (en) * 1994-10-06 1997-04-08 Cephalon, Inc. Acetamide derivative having defined particle size
GB9511220D0 (en) * 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions

Also Published As

Publication number Publication date
NZ516613A (en) 2003-08-29
CZ300151B6 (cs) 2009-02-25
HK1044278A1 (en) 2002-10-18
AU773666B2 (en) 2004-06-03
CO5200849A1 (es) 2002-09-27
AR033953A1 (es) 2004-01-21
SK286365B6 (sk) 2008-08-05
ZA200200825B (en) 2003-04-30
PE20010480A1 (es) 2001-05-26
MY125428A (en) 2006-07-31
SV2002000137A (es) 2002-06-07
HUP0202781A3 (en) 2003-10-28
HK1044278B (zh) 2004-10-08
NO321602B1 (no) 2006-06-12
PL353268A1 (en) 2003-11-03
EP1200092A2 (de) 2002-05-02
DK1200092T3 (da) 2004-08-16
WO2001008688A2 (en) 2001-02-08
PT1200092E (pt) 2004-07-30
MXPA02001197A (es) 2003-02-12
DE60010089T2 (de) 2004-10-14
CN1377270A (zh) 2002-10-30
CZ2002387A3 (cs) 2002-10-16
NO20020531L (no) 2002-04-03
PL199469B1 (pl) 2008-09-30
ES2220506T3 (es) 2004-12-16
HRP20020091B1 (en) 2006-02-28
UA71629C2 (en) 2004-12-15
AU6508400A (en) 2001-02-19
BR0012901A (pt) 2002-04-16
EA004302B9 (ru) 2019-01-31
HUP0202781A2 (hu) 2002-12-28
EP1200092B1 (de) 2004-04-21
HRP20020091A2 (en) 2004-02-29
TWI235658B (en) 2005-07-11
EA200200119A1 (ru) 2002-06-27
CA2380087C (en) 2007-05-01
EA004302B1 (ru) 2004-02-26
WO2001008688A3 (en) 2001-08-16
SK1722002A3 (en) 2002-05-09
IL147642A0 (en) 2002-08-14
DZ3180A1 (fr) 2001-02-08
ATE264680T1 (de) 2004-05-15
KR20020063842A (ko) 2002-08-05
JP4456788B2 (ja) 2010-04-28
CA2380087A1 (en) 2001-02-08
HU229443B1 (en) 2013-12-30
NO20020531D0 (no) 2002-02-01
CN101134019A (zh) 2008-03-05
JP2003505510A (ja) 2003-02-12

Similar Documents

Publication Publication Date Title
DE60010089D1 (de) Beta-carbolin arzneistoffprodukte
NO20022970L (no) Hydrogel-drevet medikamentdoseringsform
DE60016271D1 (de) Medikamentenzuführvorrichtung
NO20015175L (no) Farmasöytisk sammensetning
ATE411068T1 (de) Medikamentspender
NO20020464D0 (no) Flerkomponent-farmasöytisk doseringsform
FI4823U1 (fi) Muunnetulla tavalla vapauttava lääkeformulaatio
DK1128831T3 (da) Farmaceutisk moxifloxacinpræparat
NO20020086D0 (no) Smaksmaskerte farmasöytiske flytende formuleringer
NO20015670L (no) Forbedrede farmasöytiske formuleringer
PT1173434E (pt) Novo produto farmaceutico
NO20022606L (no) Farmasöytiske kombinasjoner
DK1275397T3 (da) Lægemiddel til lokal anvendelse
NO20014926D0 (no) Farmasöytiske forbindelser
FR2802423B1 (fr) Compositions pharmaceutiques
FI4488U1 (fi) Farmaseuttinen koostumus
NO20016430D0 (no) Farmasöytisk kompleks
AR025867A1 (es) Formulacion portasdora farmaceutica
NO20021036D0 (no) Farmasöytisk preparat
SI1200092T1 (en) Beta-carboline drug products
ATA173599A (de) Pharmazeutisches produkt
FIU990118U0 (fi) Hammaslankatuote
FIU990361U0 (fi) Hammaslankatuote
DK1183061T3 (da) Lægemiddelafgivelsessystem
UA3648S (uk) Пляшка для лікеро-горілчаних виробів

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R082 Change of representative

Ref document number: 1200092

Country of ref document: EP

Representative=s name: BOEHMERT & BOEHMERT, 28209 BREMEN, DE